Ipsen Gives Genfit Liver Drug New Lease Of Life
Pays €120m Upfront For Elafibranor Rights
The French biotech was firmly on the ropes last year after elafibranor joined the long list of failures for NASH but the promise it has shown in primary biliary cholangitis has persuaded Ipsen to part with a hefty upfront fee.
